New advances in the diagnosis and management of hepatocellular carcinoma

JD Yang, JK Heimbach - Bmj, 2020 - bmj.com
Hepatocellular carcinoma is one of the leading causes of cancer related death in the world.
Biannual surveillance for the disease in patients with cirrhosis and in high risk carriers of …

[HTML][HTML] Etiology of hepatocellular carcinoma: special focus on fatty liver disease

D Suresh, AN Srinivas, DP Kumar - Frontiers in Oncology, 2020 - frontiersin.org
Hepatocellular Carcinoma (HCC) is a highly aggressive cancer with mortality running
parallel to its incidence and has limited therapeutic options. Chronic liver inflammation and …

[HTML][HTML] Stress proteins: the biological functions in virus infection, present and challenges for target-based antiviral drug development

Q Wan, D Song, H Li, M He - Signal transduction and targeted therapy, 2020 - nature.com
Stress proteins (SPs) including heat-shock proteins (HSPs), RNA chaperones, and ER
associated stress proteins are molecular chaperones essential for cellular homeostasis. The …

[HTML][HTML] Lipid metabolism in development and progression of hepatocellular carcinoma

M Sangineto, R Villani, F Cavallone, A Romano… - Cancers, 2020 - mdpi.com
Metabolic reprogramming is critically involved in the development and progression of
cancer. In particular, lipid metabolism has been investigated as a source of energy, micro …

Efficacy of direct-acting antivirals for chronic hepatitis C virus infection in people who inject drugs or receive opioid substitution therapy: a systematic review and meta …

C Graf, MM Mücke, G Dultz, KH Peiffer… - Clinical Infectious …, 2020 - academic.oup.com
Background Treatment uptake for hepatitis C virus (HCV) infection in people who inject
drugs (PWID) and patients on opioid substitution therapy (OST) is still low despite treatment …

Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics

YM Chiu, DY Chen - Expert Review of Clinical Immunology, 2020 - Taylor & Francis
Introduction: Despite the therapeutic effectiveness of biologics targeting immune cells or
cytokines in patients with inflammatory arthritis, which reflects their pathogenic roles, an …

Global elimination of hepatitis C virus by 2030: why not?

GJ Dore, M Martinello, M Alavi, J Grebely - Nature medicine, 2020 - nature.com
Global elimination of hepatitis C virus by 2030: why not? | Nature Medicine Skip to main
content Thank you for visiting nature.com. You are using a browser version with limited support …

National prevalence rate of hepatitis B and C in Pakistan and its risk factors

S Mehmood, H Raza, F Abid, N Saeed… - Journal of Public …, 2020 - Springer
Aim The purpose of this review was to reveal the prevalence rate of viral hepatitis in
Pakistan and diverse risk factors that are associated with infections. The distribution of the …

Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists—the practitioner …

AD Marshall, J Grebely, GJ Dore, C Treloar - Drug and alcohol …, 2020 - Elsevier
Background Since the advent of interferon-free, direct-acting antiviral (DAA) therapies for
hepatitis C virus (HCV) infection, prescriber restrictions have been removed worldwide …

Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre‐and post‐universal access to direct‐acting antiviral …

S Bajis, J Grebely, B Hajarizadeh… - Journal of viral …, 2020 - Wiley Online Library
Gaps in hepatitis C virus (HCV) testing, diagnosis, liver disease assessment and treatment
uptake among people who inject drugs (PWID) persist. We aimed to describe the cascade of …